

# Donghoon Kim

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5981098/publications.pdf>

Version: 2024-02-01

18  
papers

3,100  
citations

623734

14  
h-index

839539

18  
g-index

19  
all docs

19  
docs citations

19  
times ranked

5135  
citing authors

#	ARTICLE	IF	CITATIONS
1	Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson's disease. <i>Nature Medicine</i> , 2018, 24, 931-938.	30.7	712
2	Midbrain-like Organoids from Human Pluripotent Stem Cells Contain Functional Dopaminergic and Neuromelanin-Producing Neurons. <i>Cell Stem Cell</i> , 2016, 19, 248-257.	11.1	628
3	Pathological $\alpha$ -synuclein transmission initiated by binding lymphocyte-activation gene 3. <i>Science</i> , 2016, 353, .	12.6	521
4	Graphene quantum dots prevent $\alpha$ -synucleinopathy in Parkinson's disease. <i>Nature Nanotechnology</i> , 2018, 13, 812-818.	31.5	339
5	Parthanatos mediates AIMP2-activated age-dependent dopaminergic neuronal loss. <i>Nature Neuroscience</i> , 2013, 16, 1392-1400.	14.8	182
6	$\alpha$ -Synuclein accumulation and GBA deficiency due to L444P GBA mutation contributes to MPTP-induced parkinsonism. <i>Molecular Neurodegeneration</i> , 2018, 13, 1.	10.8	143
7	GBA1 deficiency negatively affects physiological $\alpha$ -synuclein tetramers and related multimers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 798-803.	7.1	139
8	Activation of tyrosine kinase c-Abl contributes to $\alpha$ -synuclein-induced neurodegeneration. <i>Journal of Clinical Investigation</i> , 2016, 126, 2970-2988.	8.2	133
9	Blocking microglial activation of reactive astrocytes is neuroprotective in models of Alzheimer's disease. <i>Acta Neuropathologica Communications</i> , 2021, 9, 78.	5.2	82
10	The c-Abl inhibitor, Radotinib HCl, is neuroprotective in a preclinical Parkinson's disease mouse model. <i>Human Molecular Genetics</i> , 2018, 27, 2344-2356.	2.9	55
11	Parkin interacting substrate zinc finger protein 746 is a pathological mediator in Parkinson's disease. <i>Brain</i> , 2019, 142, 2380-2401.	7.6	46
12	D409H GBA1 mutation accelerates the progression of pathology in A53T $\alpha$ -synuclein transgenic mouse model. <i>Acta Neuropathologica Communications</i> , 2018, 6, 32.	5.2	26
13	TRIP12 ubiquitination of glucocerebrosidase contributes to neurodegeneration in Parkinson's disease. <i>Neuron</i> , 2021, 109, 3758-3774.e11.	8.1	26
14	Complement and Coagulation Cascades are Potentially Involved in Dopaminergic Neurodegeneration in $\alpha$ -Synuclein-Based Mouse Models of Parkinson's Disease. <i>Journal of Proteome Research</i> , 2021, 20, 3428-3443.	3.7	21
15	Amyloid-like oligomerization of AIMP2 contributes to $\alpha$ -synuclein interaction and Lewy-like inclusion. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	14
16	Estrogen receptor activation contributes to RNFI46 expression and neuroprotection in Parkinson's disease models. <i>Oncotarget</i> , 2017, 8, 106721-106739.	1.8	13
17	Lysosomal Enzyme Glucocerebrosidase Protects against A $\beta$ <sup>21-42</sup> Oligomer-Induced Neurotoxicity. <i>PLoS ONE</i> , 2015, 10, e0143854.	2.5	12
18	Pyruvate Dehydrogenase Kinase Protects Dopaminergic Neurons from Oxidative Stress in Drosophila DJ-1 Null Mutants. <i>Molecules and Cells</i> , 2022, 45, 454-464.	2.6	6